Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer

Community Oncology

Volumn 3, Issue 9, 2006, Pages 593-598

  Venook, Alan P ^a,h   Blanke, Charles D ^b   Goldberg, Richard M ^c   Reinke, Denise K ^d   Sutherland, Susan ^e   Taylor, John R ^f   McAllister, Pamela ^g   Schilsky, Richard L ^f  

^a CALGB   (United States)

^b SWOG   (United States)

^c CALGB   (United States)

^d SWOG   (United States)

^e CALGB Statistical Center   (United States)

^f CALGB   (United States)

^g NONE

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIET; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; HEALTH CARE SYSTEM; HUMAN; LIFESTYLE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; QUALITY OF LIFE; RASH; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 33751220821     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70756-2     Document Type: Review

References (31)

1. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:4553-4560.
2. Venook AP, Blanke CD, Niedzwiecki D, et al. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologies for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer 2005;5:292-294.
3. Venook A, Blanke C, Josef-Lenz H, et al. A phase III trial of irinotecan/5-FU/leucovorin or oxaliplatin/5-FU/leucovorin with bevacizumab, or cetuximab (C225), or with the combination of bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum. CALGB/SWOG C80405. Cancer and Leukemia Group B. September 2005. Available at: http://www.calgb.org. Accessed April 3, 2006.
4. Coalition of Cancer Cooperative Groups. 17,500 Participants needed to enroll in major colorectal cancer clinical trials. Available at: http://www.cancertrialsherp.org/patientsCaregivers/colorectalTrials.jsp. Accessed July 10, 2006.
5. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-20.
6. Weinerman B, Shah A, Fields A, et al. Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. Am J Clin Oncol 1992;15:518-523.
7. Kohne CH, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003;21:3721-3728.
8. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bi-monthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-815.
9. André T, Louvet C, Raymond E, Tournigand C, de Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998;9:1251-1253.
10. André T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-3568.
11. Maindrault-Goebel F, Louvet C, André T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338-1342.
12. Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001;37:1000-1005.
13. André T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:1343-1347.
14. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
15. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
16. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866-4875.
17. nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Ga. Abstract 3509.
18. van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer 2005;117:883-888.
19. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
20. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets tor anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-835.
21. Avastin [package insert]. South San Francisco, Calif: Genentech Inc; 2005.
22. Saltz LB, Lenz HJ, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. Presented at the 2005 Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, Fla. Abstract 169b.
23. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
24. Dudek AZ, Kmak KL, Koopmeiners J. Keshtgarpour M. Skin rash and bronchoalveolar histology correlate with clinical benefit in patients treated with gefitinib as a therapy tor previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 2006;51:89-96.
25. National Cancer Institute. About the community clinical oncology program. Available at: http://www.cancer.gov/prevention/ccop/facts.html. Accessed May 12, 2006.
26. National Cancer Institute. Cancer trials support unit ecourse: review module objectives. Available at: http://ecourse.ctsu.org/Learn.htm. Accessed May 12, 2006.
27. National Cancer Institute. Important Notice: Moratorium on New CTSU Independent Clinical Research Site (CICRS) Application. Available at: http://www.ctsu.org/non-group_page.asp. Accessed May 15, 2006.
28. National Cancer Institute. Cancer trials support unit ecourse: clinical trial overview. Available at: http://ecourse.ctsu.org/about. htm. Accessed May 12, 2006.
29. National Cancer Institute. Cancer trials support unit ecourse: register module objectives. Available at: http://ecourse.ctsu.org/Register.htm. Accessed May 12, 2006.
30. National Cancer Institute. CTSU Independent Clinical Research Sites (CICRS) site qualification review process. Available at: http://www.ctsu.org/ Qualif_Rev_Process.pdf. Accessed May 12, 2006.
31. National Cancer Institute. CTSU Independent Clinical Research Sites (CICRS) initiative frequently asked questions. Available at: http://www.ctsu.org/CICRS_FAQ_July2004. asp. Accessed May 12, 2006.